Phosphanilic acid is an antibacterial agent with a mode of action and antibacterial spectrum similar to those of sulfamethoxazole, with the exception that it has potent antipseudomonal activity. Bioavailability studies in rats (50, 300, and 600 mg/kg, oral and subcutaneous), dogs (50, 150, and 450 mg/kg, oral and intravenous infusion), and humans (400 and 800 mg, oral) showed that the extent of oral absorption of potassium phosphanilate was low. The bioavailability, calculated by comparing the oral values for area under the plasma concentration curve with those for the respective parenteral doses, was 10% for rats and 45 (50 and 150 mg/kg) and 19% (450 mg/kg) for dogs. The 24-h urinary recovery also confirmed the low oral bioavailability, i.e., rat, 13 (oral) and 75% (subcutaneous); dog, 15 to 29 (oral) and 87% (intravenous) of the dose. Plasma levels and urinary recovery (4%, oral) were low and variable in humans. The poor absorption of oral doses may be due to drug precipitation in the stomach, low permeability of the soluble species due to extensive in situ ionization (pKa, 1.8 to 2) in the intestine, or first-pass metabolism to N-acetylphosphanilic acid. The plasma t1/2 values after parenteral administration were 0.3 h in rats and 1.3 h in dogs. Although the lack of adequate blood levels of phosphanilic acid after oral administration in humans precludes the use of this compound for treatment of systemic infections, the sustained urinary concentration at levels severalfold higher than the minimal inhibitory concentration (1 ,ug/ml) for at least 10 h postdose was indicative of the therapeutic usefulness in urinary tract infections.
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Phosphanilic acid (p-aminobenzenephosphonic acid) is an antibacterial agent with a mode of action similar to that of the sulfonamides (p-aminobenzoic acid antagonist) (5, 6, 15) . The antibacterial spectrum is similar to sulfamethoxazole, with the exception that phosphanilic acid has potent antipseudomonal activity both in vitro and in infectious disease models in rodents (4, 8, 12 ; F. Leitner and D. Chisholn, unpublished data).
The systemic absorption and metabolism of phosphanilic acid has not been determined. Pendse and Bhide (10) showed that the compound was excreted in the uriiie after oral administration. Results of studies on the absorption and elimination of phosphanilic acid in rats, dogs, and humans after oral and parenteral administration are reported in this study. The plasma elimination half-life after parenteral administration was calculated from the slope (,B) of the linear regression line plotted through the natural logarithm (In) of C versus t data for the elimination phase. The appropriate equation was tl/2 = (In2//i).
MATERIALS AND METHODS

RESULTS AND DISCUSSION
Rat bioavailability studies. Oral absorption of potassium phosphanilate in the rats was low (Fig. 1) . The mean relative bioavailability, calculated by comparing the oral AUC values with those for the respective subcutaneous doses at 50, 300, and 600 mg/kg, was 10.0 ± 1.7% (Table 1) . At the 600 mg/kg oral and subcutaneous doses, Tmax (2 and 0.67 h for oral and subcutaneous routes, respectively) increased by about twofold from that observed at the 50 and 300 mg/kg doses. Gastrointestinal absorption of phosphanilic acid in the rats was not significantly enhanced by intraduodenal administration (Fig. 2) . The oral and intraduodenal bioavailabilities relative to the intraperitoneal dose were 5.3 and 13.1%, respectively.
The low bioavailability of the oral doses may, in part, be due to drug precipitation in the stomach (pH 1 to 3) (11). When 0.1 N HCl was added dropwise to a 10 mg/ml aqueous solution of potassium phosphanilate, the drug precipitated at a pH of 4.3 and below. Although phosphanilic acid (pK., 1.8 to 2) (3) readily redissolved when the pH was raised from 1.2 to 6.2, it would exist primarily in the ionized form (99.99%) in the intestine at pH 6 to 8. Therefore, the lack of oral absorption was also related to low membrane permeability as a result of extensive in situ ionization at the site of absorption (11) . The prolongation in Tmax could be indicative of diffusion-limited absorption of the ionized species from the subcutaneous site and dissolution-limited absorption of precipitated free acid in the gastrointestinal tract at the highest dose level studied. The high bioavailability of the intraperitoneal dose suggests that first-pass metabolism was not a significant factor in absorption in rats (7) .
The apparent plasma half-life of phosphanilic acid by the subcutaneous route was longer at the 300 and 600 mg/kg doses (0.7 and 0.8 h, .a Thirty-three rats were used in each dosing group; three rats were bled at each time point.
b Pooled urine from three rats per dose group. Table 2) . The compound was two-to fourfold more available in dogs than in rats (Table 1) , suggesting significant interspecies variation in the drug absorption. The relatively lower bioavailability for the 450 mg/kg oral dose level could be due to the same absorption limitations as observed in the rats.
The plasma half-life of phosphanilic acid by the intravenous route was 1.3 ± 0.2 h over a dose range of 50 to 450 mg/kg, suggesting linear elimination pharmacokinetics. The apparent t1/2 for the oral doses was 3.2 ± 0.8 h. This indicated that the absorption phase in the dogs, as in the rats, extended into the elimination phase.
Phosphanilic acid was eliminated primarily in the urine of the dogs. A mean of 87.1 ± 14.6% of the intravenous doses was recL vd in 0-to 24-h urine. About 14.8 + 6.0, 29.0 18.6, and 27.6 ± 8.0% of the 50, 150, and 450 mg/kg oral doses were excreted in the same period, respectively. By comparing the urinary recoveries after oral and intravenous administration, the absolute bioavailabilities were 19. 1 and day 28 of the study (Table 3) . No significant drug accumulation was apparent after 28 days of dosing. There was also no significant difference (Student's t independent test; P > 0.05) between the plasma pharmacokinetic data obtained in this study and in separate single oral dose studies (Table 2) . No significant clinicopathological findings were observed after administration of 150 to 450 mg/kg per day for 30 days.
Human bioavailability studies. Oral absorption of phosphanilic acid in man proceeded slowly, as reflected by a delay of 0.5 to 1.0 h before plasma levels were observed (Fig. 4) . Maximum plasma concentrations (Cm...) were achieved about 1.2 to 1.6 h postdose and did not exceed a mean of 1.1 + 0.4 jig/ml, even after a dose of 800 mg (Table 4 ). The mean AUC values were low and erratic: 1.0 ± 0.9 ,tg.h per ml for the 400-mg dose and 4.6 ± 2.5 pig.h per ml for the 800-mg dose. These data suggest as poor oral absorption of potassium phosphanilate in humans as in rats and dogs.
The lack ofsignificant oral absorption ofphosphanilic acid was confirmed by the low recovery of drug in the urine. The mean cumulative 24-h urinary excretion of phosphanilic acid was only about 4% of the dose at both dose levels. This urinary recovery can be considered to be a good estimate of the percentage of dose absorbed and reaching the systemic circulation.
The poor oral absorption and the lack of ad- equate blood levels of phosphanilic acid in humans precludes the systemic use of this compound for treatment of otitis media and respiratory tract infections. However, phosphanilic acid concentrations in human urine were maintained for at least 10 h postdose at levels severalfold higher than the minimal inhibitory concentration value of 1 ,ug/ml against more than 90% of Pseudomonas strains (Leitner and Chisholm, unpublished data) ( Table 5 ). These urinary concentrations were indicative of the therapeutic usefulness of phosphanilic acid as a urinary tract antiseptic when given either alone or in combination with other antimicrobial agents, e.g., trimethoprim.
In the human bioavailability study, no adverse side effects were evidenced. Hematologies, clinical chemistries, urinalyses and physical examinations performed 24 h after the 400-and 800-mg doses remained within the normal range.
Metabolism of phosphanilic acid in laboratory animals and humans. The low oral bioavailability of phosphanilic acid in humans could, in part, be due to metabolism (first-pass or otherwise). High-performance liquid chromatographic analysis of selected human urine samples from the 400-mg dose group indicated that an additional 12 to 15% of the dose was excreted as N-acetylphosphanilic acid, an antibiotically inactive derivative (10) . This metabolite was also found in the urine of the rats, but not in that of the dogs. Qualitative examination of rat and dog plasma for N-acetylphosphanilic acid by high-performance liquid chromatography demonstrated that neither species had detectable plasma levels (assay sensitivity, 5 ,g/ ml) of this metabolite. These results are in accord with previously published reports (9, 14) which indicate that acetylated amines, once formed, are rapidly excreted without accumulation in blood and that dogs, unlike rats and humans, do not acetylate aromatic amines due to the presence of an arylamine N-acetylase inhibitor or an arylamine-N-deacetylase enzyme. The absence of N-acetylation in dogs is consistent with the interspecies differences in the oral bioavailability of phosphanilic acid, which was highest in dogs (43 to 45% at doses of 50 and 150 mg/kg) and lowest in rats (about 10% at doses up to 600 mg/kg) and humans (about 4%, based upon excretion as intact drug in 24-h urine).
